# A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine

> **NCT06607380** · PHASE1 · COMPLETED · sponsor: **Zhuhai Trinomab Pharmaceutical Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Tetanus

## Interventions

- **BIOLOGICAL:** TNM002
- **BIOLOGICAL:** Adsorbed tetanus vaccine
- **BIOLOGICAL:** TNM002 + adsorbed tetanus vaccine

## Key facts

- **NCT ID:** NCT06607380
- **Lead sponsor:** Zhuhai Trinomab Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-13
- **Primary completion:** 2023-04-10
- **Final completion:** 2023-04-17
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06607380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06607380, "A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06607380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*